Gearing up for advancement.
The following documents have been filed with the SEC:
SEC Filing Alert
424B3: Prospectus [Rule 424(b)(3)]
We have registered for resale by the Selling Stockholders named herein a remaining aggregate of 278,076,375 shares of our common stock as described below.Issuer: CytoDyn Inc
Securities being offered 184,135,636 shares of common stock and 93,940,739 shares underlying outstanding warrants to purchase our common stock, as listed in the table under “Selling Stockholders” below.
Common stock outstanding prior to this offering:
1,369,733,680 shares of common stock as of May 15, 2026
Use of proceeds
We will not receive any of the proceeds from the sale or other disposition of the Shares by the selling stockholders. The selling stockholders will bear all selling and other expenses incurred in connection with the sale or other disposition by them of the Shares covered hereby. However, if all the warrants covered by this prospectus are exercised for cash, we may receive proceeds of up to approximately $23.9 million, as further described in “Use of Proceeds.”
Market for common stock
Our common stock is quoted on the OTCQB of the OTC Market under the symbol “CYDY.” On May 15, 2026, the closing price of our common stock was $0.35 per share.
Risk factors
The purchase of our securities involves a high degree of risk. See “Risk Factors” beginning on page 9 and other information included in this prospectus for a discussion of factors you should carefully consider before deciding to invest in our securities.
Market Data 
Markets 
AI
